Open Access Open Access  Restricted Access Subscription or Fee Access

Adrenaline Use for Anaphylaxis Management during COVID-19 Mass Vaccination Program in India

Gurpreet Kaur, Latika Rohilla, Sukhpal Kaur, Sanjay Verma, Manjeet Singh Singh

Abstract


On 16th January 2021, GOI launched the COVID-19 vaccination campaign.  With the introduction of the COVID-19 vaccine for the first time, there are expectations and apprehensions among the vaccine beneficiaries especially regarding the Adverse Events Following Immunization (AEFI).  Although, vaccines-related serious AEFI are rare, but if they happen, there is a need to manage it quickly and efficiently not only to prevent mortality and morbidity in the individual recipient but also to ensure there is no disruption in the program by maintaining confidence in the vaccine.  The GOI has issued guidelines to manage adverse reactions. The current review talks about the guidelines regarding adrenaline administration during the management of vaccine-induced anaphylaxis.


Keywords


Adrenaline, anaphylaxis, Covid-19 vaccine, vaccination, immunization

Full Text:

PDF

References


Ministry of Health & Family Welfare, G.O.I. COVID-19 Vaccines Operational Guidelines. Retrieved Jan 6, 2021. From https://main.mohfw.gov.in/sites/default/files/COVID19 VaccineOG111Chapter16.pdf

Ministry of Health & Family Welfare, G.O.I. Operational Guidelines: Initial Management of Anaphylaxis Using Injection Adrenaline by ANM. Retrieved Jan 7, 2021. Available from: https://nhm.gov.in/New_Updates_2018/NHM_Components/Immunization/Guildelines_for_immunization/Initial_Management_of_Anaphylaxis_using_Inj_Adrenaline_by_ANM_Operational_Guidelines.pdf

Centre for Disease Control and Prevention (CDC). Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination. Retrieved Jan 6, 2021 https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html

Song TT. Epinephrine Needle Length in Auto-injectors and Why It Matters. J Allergy Clin Immunol Pract. 2018; 6(4): 1264–65p.

Shaw H. Intramuscular Injection. Nurs Stand. 2015; 30(6): 61–2p.

Resuscitation Council (UK). Emergency Treatment of Anaphylactic Reactions. Guidelines for Healthcare Providers. Jan 2008. Annotated with Links to NICE Guidelines. July 2012. Retrieved Jan 7, 2021. Available from: https://www.resus.org.uk/sites/default/files/202006/Emergency TreatmentOfAnaphylacticReactions%20%281%29.pdf

Nicoll LH, Hesby A. Intramuscular Injection: An Integrative Research Review and Guideline for Evidence-Based Practice. Appl Nurs Res. 2002; 15(3): 149–62p.

Simons FE, Gu X, Simons KJ. Epinephrine Absorption in Adults: Intramuscular versus Subcutaneous Injection. J Allergy Clin Immunol. 2001; 108(5): 871–3p.

Commins SP. Outpatient Emergencies: Anaphylaxis. Med Clin North Am. 2017; 101(3): 521–36p.

Poland GA, Borrud A, Jacobson RM, et al. Determination of Deltoid Fat Pad Thickness: Implications for Needle Length in Adult Immunization. JAMA. 1997; 277(21): 1709–11p.

Turner Paul J, Ansotegui Ignacio J, et al. COVID-19 Vaccine-Associated Anaphylaxis: A Statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organization. Feb 2021; 14(2): 100517p. Retrieved March 12, 2021


Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Research & Reviews: Journal of Medicine